/ /

  • linkedin
  • Increase Font
  • Sharebar

    What punctal plug delivery of dexamethasone means for allergic conjunctivitis

    Treatment addresses challenges of adherence; yields better results with sustained, controlled delivery

    Take-home message: Treatment of chronic allergic conjunctivitis with a sustained-release dexamethasone resulted in better clinical results because of the sustained and controlled delivery.

    Reviewed by Eugene B. McLaurin, MD, FACS

    Memphis, TN—Sustained drug delivery for allergic conjunctivitis is a potential new treatment for the ocular and nasal signs of allergic conjunctivitis. A phase II clinical study of a punctal plug depot of dexamethasone showed evidence of both safety and efficacy over 6 weeks, the maximum time frame associated with pollen seasons in most areas.

    Related: How chronic pain syndromes and dry eye are correlated

    "We see significant advantages of using a sustained delivery system over eye drops said Eugene B. McLaurin, MD FACS, Total Eye Care, Memphis, TN.

    Dr. McLaurin provided an overview of the study that evaluated sustained-release dexamethasone for the treatment of chronic allergic conjunctivitisusing a modified Conjunctival Allergen Model.

    Related: What clinicians should know about ocular allergies

    The trial was sponsored by Ocular Therapeutix. The company launched its phase III program later in 2015. The same sustained-release dexamethasone product candidate is under review by the FDA for postsurgical pain and inflammation.

    More about the research

    Fred Gebhart
    The author is a correspondent for Urology Times, a sister publication.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results